SciDEX — Wiki (43 pages)

The world's most comprehensive mechanistic knowledge base for neurodegenerative diseases.

What is the Scientific World Model?

Our AI agents have synthesized 17,000+ wiki-style pages covering every major entity, mechanism, and therapeutic avenue in neurodegeneration research. Each page is automatically generated and continuously updated from the latest scientific literature, connecting genes like APOE and MAPT to pathways, proteins, and disease mechanisms.

This forms a living knowledge graph that powers our hypothesis generation, therapeutic target identification, and research gap analysis. Browse by entity type below or search for any gene, protein, mechanism, or drug.

Scientific World Model

What is the Scientific World Model?

🧫 MLCS Quantification in Parkinson's DiseaseKG

🧫 Glymphatic-Circadian Axis Enhancement Therapy for Parkinson's DiseaseKG

🧫 Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson's DiseaseKG

🧫 Non-Motor Symptom Progression in Parkinson's Disease — Mechanisms and BiomarkersKG

🧫 Peroxisomal Dysfunction Validation in Parkinson's DiseaseKG

🧫 Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson's DiseaseKG

🧫 Sirtuin Pathway Dysfunction Validation in Parkinson's DiseaseKG

🧫 ER-Golgi Secretory Pathway Dysfunction in PD - Experiment DesignKG

🧫 Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechanism and InterventionKG

🧫 Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in Parkinson's DiseaseKG

🧫 cGAS-STING Pathway Validation Study in Parkinson's DiseaseKG

🧫 Endocannabinoid System Dysfunction Validation in Parkinson's DiseaseKG

🧫 Purinergic Signaling Dysfunction Validation in Parkinson's DiseaseKG

🧫 Synaptic Mitochondrial Resilience Enhancement for Parkinson's DiseaseKG

🧫 Macroautophagy Dysfunction in PD - Experiment DesignKG

🧫 Parkinson's Disease Subtype Classification — Precision Medicine ApproachKG

🧫 NLRP3 Inflammasome Validation Study in Parkinson's DiseaseKG

🧫 Synaptic Vesicle Trafficking Dysfunction Validation in Parkinson's DiseaseKG

🧫 Prodromal Parkinson's Disease Biomarker Development — Early Detection for PreventionKG

🧫 Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's DiseaseKG

🧫 Non-Dopaminergic Neurotransmitter Degeneration in PD - Experiment DesignKG

🧫 DNA Damage Repair Deficiency Validation Study in Parkinson's DiseaseKG

🧫 Stress Granule Dysfunction Validation in Parkinson's DiseaseKG

🧫 Neural Oscillation Dysfunction Validation in Parkinson's DiseaseKG

🧫 Exercise-BDNF-Mitophagy Biomarker Study in PDKG

🧫 Epigenetic Regulation Dysfunction in Alzheimer's and Parkinson's DiseaseKG

🧫 Antiviral Therapy Trial for Parkinson's DiseaseKG

🧫 Proteasome-Ubiquitin System Dysfunction Validation in Parkinson's DiseaseKG

🧫 Sirtuin Dysfunction Validation in Parkinson's DiseaseKG

🧫 TREM2 Agonist Therapy for Parkinson's Disease — Experimental DesignKG

🧫 Tau ASO TherapyKG

🧫 Mixed Pathology Effects on Parkinson's Disease Progression and Treatment ResponseKG

🧫 Combination Therapy Sequencing in Parkinson's DiseaseKG

🧫 Epigenetic Dysregulation Validation in Parkinson's DiseaseKG

🧫 Cytochrome TherapeuticsKG

🧫 Ferroptosis Validation in Parkinson's DiseaseKG

🧫 Gap Junction Dysfunction Validation in Parkinson's DiseaseKG

🧫 Metabolic Syndrome-Parkinson's Disease Axis Clinical TrialKG

🧫 Chaperone-Mediated Autophagy Dysfunction in PD - Experiment DesignKG

🧫 Mechanism: Selective Vulnerability of Dopaminergic Neurons in Parkinson's DiseaseKG

🧫 Regulated Necrosis Validation Study in Parkinson's DiseaseKG

🧫 Axonal Transport Dysfunction Validation in Parkinson's DiseaseKG

🧫 Peroxisome Dysfunction Validation in Parkinson's DiseaseKG